Caroline Symmes was diagnosed with Wilms Tumor Disease a month before her fourth birthday. Throughout her treatments, her parents confronted the stark reality of childhood cancer, which posed unique challenges distinct from those of adult cancer. Despite the high cure rate associated with Caroline’s type of cancer, her aggressive tumor ultimately claimed her life.
Out of her tragedy, the Caroline Symmes Children's Cancer Endowment was established in 2014 to fund research and inspire hope in future pediatric patients and their families. Today the Teen Board explores unique efforts around the world focusing on cutting-edge organizations gaining prominence within the field of pediatric cancer research.
“Our Teen Board is honored and excited to be a part of Oncoheroes Biosciences journey of becoming the global leader in delivering new pediatric oncology drugs, along with expanding the Endowment’s reach beyond the Indianapolis, Indiana area”, stated Holyn Drook, Teen Board Chair, Philanthropy/Research Committee.
Oncoheroes extends its sincere gratitude to the Caroline Symmes Children’s Cancer Endowment and their Teen Board for their commitment to our shared mission. Thanks to this new grant, the international clinical trial to assess the efficacy of our lead-compound, volasertib, in five different types of pediatric cancer, is one step closer to launching.
The collaboration between the Caroline Symmes Children’s Cancer Endowment and Oncoheroes underscores a united front in the battle against pediatric cancer. Together, we strive to transform the landscape of childhood cancer treatment, offering new avenues of hope and healing for patients and their families.
